Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 3:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 43 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo oral solution/suspension Clear all

Conditions: Hyperinsulinemia, Insulin Resistance, Non-Alcoholic Fatty Liver Disease, Prediabetic State
Interventions: Diazoxide oral suspension, 1 mg per kg per dose, Diazoxide oral suspension, 2 mg per kg per dose, Placebo, FreeStyle Libre Pro, Deuterated water (2H2O/D2O); Drug · Device
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes
Interventions: BMS-903452, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 2
States / cities: Miramar, Florida • Austin, Texas

Conditions: Cholera
Interventions: iOWH032, Placebo, V. cholerae Challenge, Antibiotics; Drug · Other
Lead sponsor: PATH; Other
Eligibility: 18 Years to 44 Years
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteers
Interventions: TAK-915 suspension, Midazolam, Placebo, TAK-915 tablet; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Influenza
Interventions: Peramivir 200 mg, Peramivir 400 mg, Oseltamivir; Drug
Lead sponsor: BioCryst Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 41
States / cities: Mobile, Alabama • Jonesboro, Arkansas • Orange, California + 33 more

Conditions: Healthy Participants
Interventions: PF-07258669, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Diarrhea
Interventions: ACE527, Placebo; Biological
Lead sponsor: TD Vaccines A/S; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Homocystinuria
Interventions: SYNB1353; Drug
Lead sponsor: Synlogic; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Healthy
Interventions: PF-07817883, Placebo, Midazolam, Moxifloxacin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: PF-06669571; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Urinary Bladder, Overactive
Interventions: Solifenacin succinate suspension; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Opioid Use Disorder
Interventions: Placebo, MCAM; Other · Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy Subjects
Interventions: PF-06751979 single ascending dose, Placebo single dose, PF-06751979 multiple ascending dose, Placebo multiple dose, PF-06751979 multiple dose; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Glendale, California

Conditions: HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma, Anal HSIL
Interventions: EXE-346 Probiotic, Placebo, Usual Care High Resolution Anoscopy (HRA); Drug · Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy Participants
Interventions: CVL-354, Placebo; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Intraabdominal Infections
Interventions: Moxifloxacin (Avelox, BAY12-8039), Ertapenem, Amoxicillin/Clavulanate, Moxifloxacin placebo, Ertapenem placebo, Amoxicillin/Clavulanate placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 458 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: San Diego, California • Springfield, Massachusetts

Conditions: Plaque Psoriasis
Interventions: PF-06826647 tablet, PF-06826647 oral suspension, Placebo oral solution/suspension, Placebo tablet; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 109 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy Volunteers
Interventions: PF-04308515, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Healthy
Interventions: PF-06865571, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Cystic Fibrosis
Interventions: VX-828, Placebo, Itraconazole, Midazolam, Tezacaftor, VX-118, Deutivacaftor; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 12
States / cities: Hollywood, Florida • Orlando, Florida • Overland Park, Kansas + 9 more

Conditions: Infantile Spasm
Interventions: Cannabidiol Oral Solution, Placebo, Vigabatrin; Drug
Lead sponsor: Radius Pharmaceuticals, Inc.; Industry
Eligibility: 1 Month to 24 Months
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Miami, Florida • Royal Oak, Michigan • Akron, Ohio + 2 more

Conditions: Healthy
Interventions: PF-08049820, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 71 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Plaque Psoriasis
Interventions: PF-06700841 oral solution/suspension, Placebo, PF-06700841 tablet; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Renal Insufficiency, Chronic, Hyperkalemia
Interventions: Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril, Valsartan, Irbesartan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 42
States / cities: Surprise, Arizona • Tucson, Arizona • Canyon Country, California + 36 more

Search by objective public record fields.

Glycemic Effect of Diazoxide in NAFLD

Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)

Cholera Anti-Secretory Treatment Trial

Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study

Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening Influenza

A Study of Single Ascending Doses of PF-07258669 in Healthy Adult Participants

Safety and Efficacy Study of a Vaccine Against Enterotoxigenic Escherichia Coli (ETEC) to Prevent Moderate to Severe Diarrhea

Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers

A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People

A Study To Understand Safety And Plasma Concentrations Of PF-06669571 During And Following The Oral Administration Of Single And Multiple Doses Of PF-06669571 In Healthy Volunteers Under Fasted And Fed Conditions

A Study to Investigate How Safe and Effective Solifenacin Solution is in Treating Children/Adolescents With Symptoms of Overactive Bladder (OAB) Who Completed Study 905-CL-076

Safety, Tolerability, and Pharmacokinetics of MCAM in Healthy Adult Participants

First-In-Human Study Of Single And Multiple Ascending Doses Of PF-06751979

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

A Single and Multiple Ascending Dose Trial of CVL-354 in Healthy Participants

Moxifloxacin in Pediatric Subjects With Complicated Intra-abdominal Infection

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers

Single Dose Study to Assess the Safety, Tolerability and Pharmacokinetics(PK) of PF-06865571

Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis

A Study to Assess Cannabidiol Oral Solution With Vigabatrin as Initial Therapy in Participants With Infantile Spasms

A Study to Learn How Different Amounts of the Study Medicine Called PF-08049820 Are Tolerated and Act in the Body in Healthy Adults

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia